Molecular and Cellular Therapeutics, built in 1992 and renovated in 1998, is a 33,000-square-foot, free-standing, state-of-the-art facility located on the University of Minnesota St. Paul campus.Molecular and Cellular Therapeutics Facility

In accordance with the FDA regulations, the facility meets current Good Manufacturing Practices (cGMP) and current Good Tissue Practices (cGTP) standards for production and testing of biotherapeutic products.  

Design and architectural systems

MCT's overall design, architectural systems and finishes meet regulatory requirements and are consistent with the ability to integrate process equipment and process utilities (Figures 1 and 2).

MCT Upper Level

MCT Lower Level Updated

Development and production

A total of 11,000 square feet of dedicated ISO Class 7 Controlled Environment Areas and ISO Class 5 areas are available for the development and production of advanced cell-, tissue-, and gene-based therapies. There are 19 clean rooms, with the space divided into five production areas, several with negative pressure, Biosafety Level 2 capabilities.  The flexible, compliant design of the facility accommodates investigator-specific needs regarding bio-safety levels, bio-containment requirements, and project-specific gowning areas.

 As part of the University of Minnesota Office of Academic Clinical Affairs, Molecular and Cellular Therapeutics has developed extensive, highly effective relationships with many departments and centers at the University, including the Stem Cell Institute, the Diabetes Institute for Immunology and Transplantation, the Cancer Center, University of Minnesota Medical Center, Fairview, and the Institute for Therapeutics Discovery and Development.

The facility is also an excellent resource for investigators from other research institutions and commercial firms, such as start-up biotherapeutic firms, that need development services, quality management, and regulatory services for testing novel biological therapeutic products.

Current core activities

  • Quality and Compliance
  • Operations/Quality/Materials Management
  • Control of Critical Systems
  • Program Budgets/Forecasts/Cost Accounting
  • Business Plan Development
  • Project Management
  • Equipment Management
  • Document Change Control
  • Process Development/Qualification/Validation

Facility FDA registration

The MCT Facility's Drug Master File (DMF) was submitted to the FDA originally on September 7, 2004.  The DMF provides confidential detailed information about the MCT Facility, processes, and articles used in the manufacturing,processing, packaging, and storing of biotherapeutics and drugs.  While the submission of a DMF is not required by law or FDA regulation, it is submitted solely at the discretion of the holder in support of IND or New Drug Applications.